154 related articles for article (PubMed ID: 32772613)
1. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience.
Viste E; Vinje CA; Lid TG; Skeie S; Evjen-Olsen Ø; Nordström T; Thorsen O; Gilje B; Janssen EAM; Kjosavik SR
Scand J Prim Health Care; 2020 Sep; 38(3):315-322. PubMed ID: 32772613
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
3. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
4. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
Palsdottir T; Grönberg H; Hilmisson A; Eklund M; Nordström T; Vigneswaran HT
Eur Urol Focus; 2023 May; 9(3):455-462. PubMed ID: 36522257
[TBL] [Abstract][Full Text] [Related]
5. The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.
Möller A; Olsson H; Grönberg H; Eklund M; Aly M; Nordström T
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):137-142. PubMed ID: 30171228
[TBL] [Abstract][Full Text] [Related]
6. Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms.
Nordström T; Engel JC; Bergman M; Egevad L; Aly M; Eklund M; Palsdottir T; Grönberg H
Eur Urol Open Sci; 2021 Feb; 24():11-16. PubMed ID: 34337490
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
Hao S; Heintz E; Östensson E; Discacciati A; Jäderling F; Grönberg H; Eklund M; Nordström T; Clements MS
Eur Urol; 2022 Jul; 82(1):12-19. PubMed ID: 35094896
[TBL] [Abstract][Full Text] [Related]
8. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study.
Waldén M; Aldrimer M; Lagerlöf JH; Eklund M; Grönberg H; Nordström T; Palsdottir T
Eur Urol Open Sci; 2022 Apr; 38():32-39. PubMed ID: 35495282
[TBL] [Abstract][Full Text] [Related]
9. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging.
Palsdottir T; Nordström T; Aly M; Jäderling F; Clements M; Grönberg H; Eklund M
Eur Urol Oncol; 2019 Sep; 2(5):490-496. PubMed ID: 31412016
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
[TBL] [Abstract][Full Text] [Related]
11. The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics-Real-world Evidence from 2018 to 2022.
Palsdottir T; Söderbäck H; Jäderling F; Bergman M; Vigneswaran H; Grönberg H
Eur Urol Open Sci; 2024 Mar; 61():29-36. PubMed ID: 38384438
[TBL] [Abstract][Full Text] [Related]
12. Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening.
Andersson J; Palsdottir T; Lantz A; Aly M; Grönberg H; Egevad L; Eklund M; Nordström T
Eur Urol Open Sci; 2022 Oct; 44():69-75. PubMed ID: 36185581
[TBL] [Abstract][Full Text] [Related]
13. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.
Nordström T; Adolfsson J; Grönberg H; Eklund M
BMC Urol; 2017 Oct; 17(1):92. PubMed ID: 28974201
[TBL] [Abstract][Full Text] [Related]
14. Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test.
Vigneswaran HT; Palsdottir T; Olsson H; Haug ES; Picker W; Löffeler S; Grönberg H; Eklund M; Nordström T
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):457-464. PubMed ID: 33168965
[TBL] [Abstract][Full Text] [Related]
15. Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI.
Nordström T; Jäderling F; Carlsson S; Aly M; Grönberg H; Eklund M
BMJ Open; 2019 Jun; 9(6):e027816. PubMed ID: 31201191
[TBL] [Abstract][Full Text] [Related]
16. Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies.
Dimmen M; Vlatkovic L; Hole KH; Nesland JM; Brennhovd B; Axcrona K
BJU Int; 2012 Jul; 110(2 Pt 2):E69-75. PubMed ID: 22093091
[TBL] [Abstract][Full Text] [Related]
17. Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging.
Vinje CA; Vigmostad MN; Kjosavik SR; Grönberg H; Gilje B; Skeie S
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37805292
[TBL] [Abstract][Full Text] [Related]
18. Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort.
Vigneswaran HT; Discacciati A; Gann PH; Grönberg H; Eklund M; Abern MR
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):120-127. PubMed ID: 32641739
[TBL] [Abstract][Full Text] [Related]
19. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
20. Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study.
Palsdottir T; Nordström T; Aly M; Lindberg J; Clements M; Egevad L; Grönberg H; Eklund M
PLoS One; 2019; 14(6):e0218280. PubMed ID: 31194822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
